CoChat

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia

Fonseca, Guilherme Wesley Peixoto Da, von Haehling, Stephan · 2021 · Expert Opinion on Pharmacotherapy

Abstract

INTRODUCTION: Cancer cachexia is a complex multifaceted syndrome involving functional impairment, changes in body composition, and nutritional disorders. The treatment of cancer cachexia can be based on these three domains of the syndrome. Phase II and III trials of anamorelin, a ghrelin mimetic agent, have been shown to increase body weight in patients with cancer cachexia, mainly by increasing muscle and fat mass. Anamorelin has been shown to improve anorexia scores. AREAS COVERED: This review aims to outline the effect of anamorelin on body composition and functional parameters as well as to discuss the clinical importance of these alterations in patients with cancer cachexia. EXPERT OPINION: To date, there is no treatment approved to enhance body composition and functional parameters in patients with cancer cachexia. Anamorelin, the most advanced therapy to treat cachexia, has not yielded convincing results in all aspects of the syndrome. In particular, no effect has been noted on physical function and long-term survival. Along with these essential improvements for future interventions with anamorelin, subsequent studies must address other etiologies of cancer, rather than non-small cell lung cancer, and add complementary therapies, such as exercise training and nutritional interventions, in an attempt to overcome cancer cachexia.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2021.1873954

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 64 references

Research works printed but not linked: 6

  1. Cole CL, 2018, JCSM Clin Rep, 3
  2. Fonseca GWPD, 2020, Int J Mol Sci, 21(7):2321
  3. Dev R, 2017, Oncology (Williston Park), 31, 23
  4. Shimizu Y, 2003, Clin Cancer Res, 9, 774
  5. Porporato PE, 2013, J Clin Invest, 123, 611
  6. Mitchell T, 2019, Healthcare (Basel), 7(3):89

Cited by

See all 25

Metadata

Authors
Fonseca, G. W. P. D., & von Haehling, S.
Affiliations
  • Universidade de São Paulo (BR)
  • Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Göttingen, Germany;s German Centre for Cardiovascular Research (DZHK) Partner Site Göttingen, Göttingen, Germany
Venue
Expert Opinion on Pharmacotherapy
Published
2021-01-25
Volume
22
Issue
7
Pages
889-895
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W3122969614
Cited by
25
References
64
Citations by year
2026: 2 · 2025: 1 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 4
FWCI
0.73
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil
  • German Center for Cardiovascular Research
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
anamorelin, cancer cachexia, ghrelin receptor agonist, body composition, muscle mass, fat mass, physical function, non-small cell lung cancer, dietary intervention, exercise training
MeSH terms
Anorexia, Cachexia, Carcinoma, Non-Small-Cell Lung, Humans, Hydrazines, Lung Neoplasms, Neoplasms, Oligopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia. https://app.cochat.ai/papers/10.1080/14656566.2021.1873954
The paper
Fonseca, G. W. P. D., & von Haehling, S. (2021). An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2021.1873954

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.